How to care about insulin resistance, and cardiovascular risk?

Efficient treatment of diabetes mellitus and arteriosclerosis and their associated macrovascular complications is one of the biggest clinical challenges today.

Typ 2 Diabetes – Early detection of disease development is possible!

Elevated fasting morning levels of intact proinsulin are a highly specific indicator for an advanced damage of the insulin-producing cells of the pancreas (ß-cell dysfunction), and also for a clinically relevant insulin resistance. Both conditions are causes of type 2 diabetes. Current diagnosis of type 2 diabetes is still exclusively made based on measurement of elevated blood glucose levels or increasing levels of the glycosylated fraction of hemoglobin A1c (HbA1c). This approach does not make use of the opportunity to predict disease development by measurement of intact proinsulin at a very premature stage.    

Arteriosclerosis

Arteriosclerosis is characterized especially by an accumulation of cholesterol containing fatty deposits (plaques) in the inner layers of the arteries. With increasing plaque volume the lumen of the arteries will decrease and the blood flow will be impaired.

In the context of arteriosclerosis, the functionality of the endothelial glycocalix (the inner layer of the arteries) is impaired and cannot perform efficient substance transfer anymore, which is required to support vascular protection and repair mechanisms. A targeted re-modelling of this glycocalix represents a new and promising treatment approach.

BelDIA PRE - Screening Test having the risk getting Typ II Diabetes

Prediction of risk for Type 2 Diabetes development.

BelDIA PRE® is an easy to use screening test device for patients, clinics and physians. By determination of fasting plasma concentration of intact proinsulin, the test describes development of type 2 diabetes mellitus even up to one years prior to glucose elevation. It is designed as a point-of-care device to provide immediate results.

The early test is working with a lateral-flow based technology similar to a pregnancy test. The result is provided in a qualitative way and is either “positive” or “negative”. One drop of blood capillary blood (40 µl) is needed, e.g. obtained by pricking the fingertip.

Read more: BelDIA PRE - Screening Test having...

BelDIA PRE – Screening of intact proinsulin

Proinsulin: A Pathophysiological Background

Proinsulin is the prohormone precursor to insulin made in the beta cells of the islets of Langerhans, specialized regions of the pancreas responsible for insulin production and secretion. In humans, the INS gene encodes proinsulin.

Insulin resistance (IR) and deterioration of beta-cell secretion are main features in the development of type 2 diabetes, which is reflected by increasing serum intact Proinsulin levels. ntroduction of stable assays that are able to distinguish between intact Proinsulin and its specific and unspecific cleavage products has resulted in the finding that serum intact Proinsulin values can serve as a direct marker for beta-cell dysfunction, are a highly specific indicator of IR, and can predict cardiovascular risk.

Read more: BelDIA PRE – Screening of intact...

BelCARDIO - Rapid Test for Myocardial Infarction

Has my patient an acute myocardial infarction?

If a patient just had a cardiac attack, this person can tell a medical professional about the symptoms. Some symptoms like tightness in the chest with acute pain in the left shoulder and arm are typical signals for a heart attack. However there are other symptoms like pain in the stomach or in the belly that could be caused by a cardiac infarction. Otherwise such symptoms can originate from other diseases. It’s always a challenge for every physician or medical professional to find the correct diagnose.

With BelCARDIO you can determine immediately whether a hospitalization is necessary or if other reasons are the cause for thorax pain. A quick decision can help the patient and it’s a relief for your daily work.

 

Read more: BelCARDIO - Rapid Test for Myocardial...

BelCARDIO - Invitro Diagnosticum indicates a myocardial infarction

The BelCARDIO Concept

Invitro Diagnostikum - Qualitative test for assessment of heart-specific FABP and cardiac Troponin I in human capillary blood, serum, or plasma.

The determination of the early-phase protein hFABP next to Troponin I in the BelCARDIO test increases the diagnostic sensitivity for acute myocardial infarctions and Non-ST-elevation myocardial infarctions (NSTEMI). The combination of the most rapid biomarker hFABP and Troponin I represents a new generation of point-of-care tests for cardiac events. A broad diagnostic window is covered with just one test.

Read more: BelCARDIO - Invitro Diagnosticum...

Arteriosclerosis, a silent and severe disease

Disease Number one, worldwide: arteriosclerosis!

The drug provided by PharmACT AG is named „BelACT®“ (A- Ateriosclerosis, C- Clean, T- Therapy) and will change the treatment of cardiovascular diseases on a worldwide basis.

Arteriosclerosis is characterized especially by an accumulation of cholesterol containing fatty deposits (plaques) in the inner layers of the arteries. With increasing plaque volume the lumen of the arteries will decrease and the blood flow will be impaired. If the coronary blood vessels (coronary arteries) are involved characteristic chest pain is his consequence (angina pectoris). Despite the relatively high success rates neither the balloon angioplasty nor the arterectomy or stents are perfect.

BelACT - Therapy of Arteriosclerosis by using a new medicine

Therapy with new pharmaceutical

In the context of atherosclerosis, the functionality of the endothelial glycocalix (the inner layer of the arteries) is impaired and cannot perform efficient substance transfer anymore, which is required to support vascular protection and repair mechanisms. A targeted re-modelling of this glycocalix represents a new and promising treatment approach.

During the timeframe of the last 10 years we could show, that the combination of pharmaceutical and treatment an abatement of arteriosklerosis allows. This patented combination is important part of the scale of benefits from PharmACT AG.

Read more: BelACT - Therapy of Arteriosclerosis...

BelACT - Our Therapy Concept

Therapy of arteriosclerosis with "BelACT"

The PharmACT AG has developed a medication and a therapeutical concept having the potential to change the treatment of cardiovascular diseases on a worldwide basis.

We have integrated our concept in our company name:  The outstanding ACT treatment comprises the disease, A – Arteriosclerosis, C – Clean, and T – Therapy.

Read more: BelACT - Our Therapy Concept

What is this: Arteriosclerosis?

Arteriosclerosis – an accumulation of deposits of cholesterol and fatty acids


Cardiovascular diseases are the most common cause of death on a worldwide basis. In Germany alone, these amount to ca. 40,2% of all death cases annually. According to the Statistical Governmental Agency in Wiesbaden this corresponds to ca. 342.000 death cases in Gemany.

Read more: What is this: Arteriosclerosis?

Subcategories

Typ 2 Diabetes – Early detection of disease development is possible!

Elevated fasting morning levels of intact proinsulin are a highly specific indicator for an advanced damage of the insulin-producing cells of the pancreas (ß-cell dysfunction), and also for a clinically relevant insulin resistance. Both conditions are causes of type 2 diabetes. Current diagnosis of type 2 diabetes is still exclusively made based on measurement of elevated blood glucose levels or increasing levels of the glycosylated fraction of hemoglobin A1c (HbA1c). This approach does not make use of the opportunity to predict disease development by measurement of intact proinsulin at a very premature stage.    

Acute myocardial infarction – safe detection few minutes after first symptoms!

Even for an experienced physician it's not easy to diagnose a myocardial infarction. Only about 20% of patients with pain in the chest just had a heart attack. The majority of the patients with the same or with similar symptoms suffer from other diseases. On the other hand a myocardial infarction can show symptoms that can lead to a misinterpretation. Hence it's a huge benefit for the physician and for the patient as well if a rapid and doubtless test can show within minutes whether there was a myocardial infarction or something else.

Arteriosclerosis

Arteriosclerosis is characterized especially by an accumulation of cholesterol containing fatty deposits (plaques) in the inner layers of the arteries. With increasing plaque volume the lumen of the arteries will decrease and the blood flow will be impaired.

In the context of arteriosclerosis, the functionality of the endothelial glycocalix (the inner layer of the arteries) is impaired and cannot perform efficient substance transfer anymore, which is required to support vascular protection and repair mechanisms. A targeted re-modelling of this glycocalix represents a new and promising treatment approach.